Tamsulosin
- Generic Name
- Tamsulosin
- Brand Names
- Flomax, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5S
- CAS Number
- 106133-20-4
- Unique Ingredient Identifier
- G3P28OML5I
- Background
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.
Tamsulosin was first approved by the FDA on April 15, 1997.
- Indication
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
- Associated Therapies
- -
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Drug: FinasterideDrug: TamsulosinDrug: Tamsulosin-matching placeboDrug: Finasteride-matching placebo
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1
- Registration Number
- NCT01534351
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
- Conditions
- Healthy SubjectsPharmacokineticsCardiovascular
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT01489696
- Locations
- 🇬🇧
Covance CRU Ltd, Leeds, United Kingdom
Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
- Conditions
- Lower Urinary Tract Symptoms
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Timothy Boone, MD, PhD
- Target Recruit Count
- 10
- Registration Number
- NCT01457573
- Locations
- 🇺🇸
The Methodist Hospital System, Houston, Texas, United States
Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement
- Conditions
- Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 742
- Registration Number
- NCT01294592
- Locations
- 🇬🇧
GSK Investigational Site, High Heaton, Newcastle Upon Tyne, United Kingdom
Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT01215708
- Locations
- 🇧🇷
Clinics Hospital of University of Sao Paulo, Sao Paulo, Brazil
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Apsen Farmaceutica S.A.
- Registration Number
- NCT01203371
- Locations
- 🇧🇷
Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2010-06-23
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT01149746
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT01149733
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
- Conditions
- Urethral Sphincter Activity
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 56
- Registration Number
- NCT01028014
- Locations
- 🇺🇸
University of Alabama at Birmingham, The Kirklin Clinic, Birmingham, Alabama, United States
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 511
- Registration Number
- NCT00970632
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.